A retrospective analysis of 127 patients found that only 5 percent-level few exceeded 20 Gy cumulative kidney dose after ...
Pfizer Inc. PFE on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as ...
(n=6) remain disease-free more than two years after treatment; 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at ...
Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...
A retrospective study evaluated long-term outcomes and the feasibility of treatment cessation in patients with metastatic HSPC who achieved a response to initial therapy.
Darolutamide improved metastasis-free survival alongside hormone therapy and radiotherapy in very high-risk prostate cancer.
From Trial Results to Clinical Implications / cancer, cancer care, Cancer research, cancer treatment, clinical trials, ESMO, ...
Jideytro, ROS1 inhibitor in TKI-naive, was presented at WCLC a couple of weeks ago, again demonstrating best-in-class efficacy. And based on this data, FDA is going to review the first-line label, ...
Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today ...
A 61-year-old man's cerebellopontine angle tumor showed high-grade fetal adenocarcinoma features, but no lung primary could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results